X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
Luye Pharma grants Auriga exclusive distribution and marketing rights for Seroquel® (quetiapine fumarate, immediate release formulation) and Seroquel XR® (extended release formulation) in Singapore.
Lead Product(s): Quetiapine Hemifumarate
Therapeutic Area: Psychiatry/Psychology Product Name: Seroquel
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: DCH Auriga
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 13, 2022
Details:
Luye grants ICI Pakistan exclusive rights to distribute Seroquel (quetiapine fumarate, immediate release) and Seroquel XR (extended release formulation), atypical anti-psychotic medicines with antidepressant properties, for schizophrenia & bipolar disorder, in Pakistan.
Lead Product(s): Quetiapine Hemifumarate
Therapeutic Area: Psychiatry/Psychology Product Name: Seroquel
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: ICI Pakistan Limited
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 26, 2022
Details:
Quetiapine fumarate Extended-Release Tablets acts as dopamine type 2 (D2) and serotonin type 2A (5HT2A) antagonism, which is indicated for the treatment of Schizophrenia and Bipolar I disorder.
Lead Product(s): Quetiapine Hemifumarate
Therapeutic Area: Psychiatry/Psychology Product Name: Seroquel XR
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 17, 2022
Details:
Luye grants Zuellig exclusive rights to distribute Seroquel (quetiapine fumarate, immediate release) and Seroquel XR (extended release formulation), atypical anti-psychotic medicines with antidepressant properties, for schizophrenia & bipolar disorder, in Malaysia and Brunei.
Lead Product(s): Quetiapine Hemifumarate
Therapeutic Area: Psychiatry/Psychology Product Name: Seroquel
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Zuellig Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 02, 2021
Details:
Luye Pharma grants Distriphil the exclusive distribution and marketing rights for the central nervous system drugs Seroquel® (quetiapine fumarate, immediate release) and Seroquel XR® (extended release formulation) in the Philippines.
Lead Product(s): Quetiapine Hemifumarate
Therapeutic Area: Psychiatry/Psychology Product Name: Seroquel
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Distriphil
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership November 26, 2020
Details:
Luye grants Distriphil exclusive rights to distribute Seroquel (quetiapine fumarate, immediate release) and Seroquel XR (extended release formulation), atypical anti-psychotic medicines with antidepressant properties, for schizophrenia & bipolar disorder, in the Philippines.
Lead Product(s): Quetiapine Hemifumarate
Therapeutic Area: Psychiatry/Psychology Product Name: Seroquel
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Distribution Solutions
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 26, 2020
Details:
The potential advantage of this alternative dosage form of Quetiapine Fumarate is that it may be preferred for adult patients who experience swallowing difficulties or for adults and adolescents who have trouble swallowing tablets.
Lead Product(s): Quetiapine Hemifumarate
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 07, 2020
Details:
Luye Pharma granted exclusive promotional rights to CAP ALTER PHARMA, INC (Alter-Pharma) for Seroquel products in 9 countries and regions including Costa Rica, Jamaica, Trinidad and Tobago, Barbados, Aruba, Curacao, Bahamas, Bermuda and The Cayman Islands.
Lead Product(s): Quetiapine Hemifumarate
Therapeutic Area: Psychiatry/Psychology Product Name: Seroquel
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: CAP ALTER PHARMA
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 11, 2020
Details:
Luye Pharma granted Alvogen Korea, Zuellig Pharma and DKSH exclusive distribution and marketing rights to Seroquel® (quetiapine fumarate, immediate release) and Seroquel XR® (extended release formulation) in their respective regions of South Korea, Hong Kong and Thailand.
Lead Product(s): Quetiapine Hemifumarate
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Alvogen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 01, 2020
Details:
Moksha8 subsideries, Moksha8 Brasil Distribuidora e Representação de Medicamentos Ltda and Moksha8 Farmacéutica, S. de R.L. de C.V have been granted the exclusive promotion rights for the two central nervous system (CNS) drugs: Seroquel® and Seroquel XR® in Brazil and Mexico.
Lead Product(s): Quetiapine Hemifumarate
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Moksha8
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 14, 2020
Details:
Luye grants Cipla exclusive rights to distribute Seroquel (quetiapine fumarate, immediate release) and Seroquel XR (extended release formulation), atypical anti-psychotic medicines with antidepressant properties, in South Africa, Namibia and Botswana.
Lead Product(s): Quetiapine Hemifumarate
Therapeutic Area: Psychiatry/Psychology Product Name: Seroquel
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cipla
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 13, 2020
Details:
Luye Pharma granted the distribution and marketing rights to Cipla Medpro in South Africa and neighbouring countries on the basis of its robust business network and resources in local markets.
Lead Product(s): Quetiapine Hemifumarate
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cipla Medpro
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 10, 2020
Details:
This acknowledgement represents the third of several oral suspensions in neuroscience that OWP Pharmaceuticals hopes to commercialize over the next several years via a 505(b)(2) application.
Lead Product(s): Quetiapine Hemifumarate
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
